Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITAC: Anti-coronavirus hyperimmune IVIG plus remdesivir in hospitalized adults with COVID-19
jRCT2031200174Phase 3Completed
- Sponsor
- Funded by the National Institute of Allergy and Infectious Diseases / National Institutes of Health
- Start
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of hyperimmune intravenous immunoglobulin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Funded by the National Institute of Allergy and Infectious Diseases / National Institutes of Health. Primary endpoint: Primary clinical status at Day 7. Started Dec 2020; status: completed.
02
Drugs
hyperimmune intravenous immunoglobulin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031200174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200174.